Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

infant formula

  • Home
  •  
  • infant formula



  • Most Read
  • Latest Comments
  • Bubs enrols 400th infant in its US clinical trials to get baby formula approval
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Bubs enrols 400th infant in its US clinical trials to get baby formula approval
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Bubs enrols 400th infant in its US clinical trials to get baby formula approval
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Bubs enrols 400th infant in its US clinical trials to get baby formula approval
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Bubs enrols 400th infant in its US clinical trials to get baby formula approval
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Bubs enrols 400th infant in its US clinical trials to get baby formula approval
    Bubs enrols 400th infant in its US clinical trials to get baby formula approval
    • News

  • Bubs Australia rebounds in China after CEO fiasco, sees USA growth
    Bubs Australia rebounds in China after CEO fiasco, sees USA growth
    • News

  • Softer infant formula demand in Middle East, China and EU squeeze Clover’s profits
    Softer infant formula demand in Middle East, China and EU squeeze Clover’s profits
    • News

  • Bubs goes full steam ahead with US FDA trials in rising market for infant formula
    Bubs goes full steam ahead with US FDA trials in rising market for infant formula
    • News

  • Bubs presents its rebound plan after bitter breakup with former CEO and Chairman
    Bubs presents its rebound plan after bitter breakup with former CEO and Chairman
    • News

  • Bubs enrols 400th infant in its US clinical trials to get baby formula approval
    • News

    Bubs enrols 400th infant in its US clinical trials to get baby formula approval

    Under its old business model, the number 4 would typically never be marketed to their major customers but under the new direction of infant formula company Bubs Australia (ASX: BUB), its a joyous occasion with the 400th infant enrolled in their clinical trial program which seeks regulatory approval for commercial sales in the United States. 

    Read More
    Public
  • Softer infant formula demand in Middle East, China and EU squeeze Clover’s profits
    • News

    Softer infant formula demand in Middle East, China and EU squeeze Clover’s profits

    In 2023, global birth rates dipped by 1.15% per 1000 people, with significant declines noted in the EU (5.9%) and China (2.3%), extending a five-year trend. Consequently, all stages of infant formula production, from birth to growing milk, have declined. As a result, Clover Corporation (ASX: CLV), an Aussie tech company specialising in infant formula

    Read More
    Public
  • Bubs presents its rebound plan after bitter breakup with former CEO and Chairman
    • News

    Bubs presents its rebound plan after bitter breakup with former CEO and Chairman

    A bitter boardroom spat has left baby formula company Bubs Australia (ASX: BUB) scrambling to undertake serious damage control following a disappointing year, financially, and fruitless attempts at chasing debts created by previous management. In an attempt to calm shareholder unrest, the Company has presented its strategic review to start over. During the three-year period

    Read More
    Public
  • Synlait receives permit renewal to supply baby formula to the Chinese market
    • News

    Synlait receives permit renewal to supply baby formula to the Chinese market

    China has emerged as a hotspot for baby formula export from Australia and New Zealand. Imported baby formula holds a significant 56% share of the total market, making it one of the leading export commodities from both countries. These imported formulas will be valued at an estimated US$32 billion by 2023, according to Euromonitor, driven

    Read More
    Public
  • Bubs Australia founder and CEO forced out for alleged failure to comply with board directions
    • News

    Bubs Australia founder and CEO forced out for alleged failure to comply with board directions

    Just a month after Bubs Australia (ASX: BUB) announced that executive chairman Dennis Lin would be removed from the business, the baby milk formula company announced another shake up of its executive line up. Perhaps a foreseeable one, this time founder and CEO Kristy Carr was terminated from her position with immediate effect due to

    Read More
    Public
  • China revenue falls 66% as Bubs reports declining sales
    • News

    China revenue falls 66% as Bubs reports declining sales

    The infant formula market has more than doubled over the past decade. But not all companies have managed to keep up, thus making it a lucrative market for the few that have. Infant formula companies, like Bubs Australia (ASX: BUB), saw it as an opportunity to expand into global markets, even becoming one of the

    Read More
    Public
  • 1
  • 2
  • 3

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.